Business
Lantheus to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
BEDFORD, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company

About this update from Lantheus Holdings, Inc.
BEDFORD, Mass. , Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Brian Markison , Chief Executive Officer, will present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 7:00 a.m. ET on Tuesday, September 9 . To access the live webcast of the presentation, please visit the Investors section of the Company’s website at www.lantheus.com . A replay of the webcast will be available on the Company’s website for at least 30 days following the live presentation. About Lantheus Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey , Canada , Germany , Sweden and Switzerland , Lantheus has been providing radiopharmaceutical solutions for nearly 70 years. For more information, visit www.lantheus.com . Contacts: Mark Kinarney Vice President, Investor Relations978-671-8842 [email protected] Melissa Downs Executive Director, External Communications 646-975-2533 [email protected] Source: Lantheus Holdings, Inc.
View stock analysis, news, and events for Lantheus Holdings, Inc.
More from Lantheus Holdings, Inc.
Lantheus Announces FDA Approval of TAUKLARIFY™ (Florquinitau F 18 Injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer’s Disease
August 14, 2026
Lantheus Holdings Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lantheus Holdings...
August 7, 2026